Merkava Holdings is the investment arm of the Philip E. Werthman Trust. Dr. Philip Werthman is a surgeon, military historian, venture capitalist, inventor and entrepreneur who is investing in and helping early and mid-stage companies grow. His extensive global network of physicians, scientists, businessmen, generals, and military leaders, athletes, celebrities, entrepreneurs, investors, sports and entertainment executives, and financiers combined with international high-level government relationships allow Dr. Werthman to assemble necessary infrastructure and relationships to grow companies, add value, and distribute products around the world.
VENTURE CAPITAL / GLOBAL DISTRIBUTION
HEALTH & WELLNESS
BIOTECH • SOFTWARE
PHARMA • WIRELESS
AEROSPACE & DEFENSE
REAL ESTATE
PORTFOLIO COMPANIES
ADVISOR/BOARD
MEMBER
PRODUCT DISTRIBUTION
ABOUT US
MERKAVA MISSION
To take an active or lead role in companies that have the potential to make a positive impact on humanity leveraging our unique set of skills and relationships that bring new technologies, platforms, and ideas together with the human resources and financing necessary to improve the quality of life globally.
At Merkava, we work on an amalgamation of three credos taken from the British Special Air Service, Israeli Air Force Special Operations Unit and US Navy Seals. “Those who dare, win”, “The hard things we do quickly and the impossible takes a bit longer” and “The only easy day was yesterday” We work by assessing risk and taking action when the reward seems well worth it. We will go around, above, and if necessary, through any obstacles and once we set an objective we will work tirelessly to achieve it.
OUR FOCUS
Our focus is on venture stage companies in life sciences, biotech, high tech, wireless, pharma, CBD, software, aerospace, security and defense as well as real estate development and financing.
We target companies with some of the following qualities;
-
Platform technologies that will revolutionize the way problems are solved in biotech, aerospace, wireless communications and semiconductor microprocessing
-
Technologies that will aid in the early diagnosis and management of difficult to treat diseases
-
Pharmaceutical companies focused on organic, natural and healthier medicines and biocompounds
-
Real estate investments in mature projects or development in excellent growth locations acquired at attractive pricing
-
Companies where we can add value through our already existing strong international relationships, global financing and distribution networks.
Dr. Werthman brings his diverse background and business development skills to companies within and outside of the investment portfolio in an advisory or board capacity helping to unlock their potential.
NEWS
Emulait Announces $11M Series A Round For the First Biometric Baby Feeding System
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia
BGT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE® platform, today announced the submission of an
Amydis Receives $3.4 million NIH Commercialization Readiness Pilot Grant Award to Map Heterogeneity of Alzheimer’s Diseases in Human Clinical Trial Using Novel Retinal Tracer
Amydis Launches Phase 2 Glaucoma Clinical Program Using Novel Retinal Tracer to Detect Amyloid Beta
Clinical trial of oral ALS therapy SPG302 is enrolling in Australia
Spinogenix Receives Approval from the Australia Human Research Ethics Committee to Initiate a Phase 1 Human Clinical Trial of SPG302, a Novel Regenerative Drug for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Novel regenerative drug, SPG302 promotes functional recovery of diaphragm muscle activity after cervical spinal cord injury
Amydis Awarded Third Grant From The Michael J. Fox Foundation To Support First-In-Human Study of a Retinal Tracer for Parkinson’s Disease
Trial to Detect Alpha-Synuclein Deposits in Patients’ Eyes Underway | AMDX-2011P Tracer Aims to Aid Monitoring, Diagnosing Parkinson’s | Parkinson’s News Today
Amydis Announces Enrollment of First Participants in PROBE, a Phase 1/2a Trial Evaluating a Novel Retinal Tracer in People with Amyotrophic Lateral Sclerosis or Parkinson’s Disease
GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650 — GlobeNewswire
Amydis Receives NIH Grant Award to Develop a Novel TDP-43 Retinal Tracer in Patients with ALS and FTD
ILiAD Biotechnologies Receives NIH Grant to Develop Novel Tuberculosis Vaccine using proprietary B-Tech Vector Platform | Business Wire
Amydis Appoints Dr. Robert N. Weinreb as First Chair of Scientific Advisory Board
PR NEWSWIRE: GT Biopharma Presents TriKE® Nanobody Pipeline (GTB-5550) Preclinical Multiple Myeloma Proof-of-Concept Data at 2022 EBMT Annual Meeting
GT Biopharma Presented Preclinical Data Demonstrating Novel Mesothelin-Targeted TriKE® Driving Cytotoxicity Across All Stages of Non-Small Cell Lung Cancer at ESMO TAT 2022
4medica Renews Focus on Improving Healthcare Data Quality in 2022 – 4medica
CD Healthcare Infrastructure Partners Facilitates Consumer-Centric Healthcare Delivery on the Philadelphia Main Line
GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021 :: GT Biopharma, Inc. (GTBP)
ILiAD Biotechnologies Announces First School-Age Participants Enrolled in BPZE1 Pertussis Vaccine Phase 2b SUPER Clinical Trial | Business Wire
FDA Grants ILiAD Biotechnologies Fast Track Designation for Next Generation Pertussis Vaccine BPZE1
CD Health Infrastructure Partners Facilitates Consumer‐Centric Healthcare Delivery on the Main Line
Amydis Announces Successful Completion of a Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer Targeting TDP43 for the Diagnosis of ALS
Amydis Announces Successful Completion of a Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer Targeting TDP43 for the Diagnosis of ALS
ResQR© Comprehensive Quality CPR AID Improves Performance of CPR Compressions in Untrained Laypersons – JEMS
Medicine Startup Genexa Raises $60 Million From VC-Led Group Including Gwyneth Paltrow, Don Cheadle
GT Biopharma Announces Issuance of Two New Patents Covering TriKE® Platform Technologies
BEVERLY HILLS, Calif., Sept. 9, 2021 /PRNewswire/ — GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, today announced that the United States Patent and Trademark Office (USPTO) has issued 2 new patents: Patent No. 11,098,100 – Broad coverage for TriKE proteins targeting any antigen Patent No.
Marshfield Clinic Health System Partners with 4medica to Modernize and Build Laboratory Reference and Outreach Business – 4medica
LifeScan and Cecelia Health Sign Expanded Multi-Year Partnership to Offer Live Diabetes Telehealth Support in Combination with OneTouch® Solutions Integrated Holistic Health Tools and OneTouch® Blood Glucose Monitoring
Former Los Angeles County Sheriff Jim McDonnell Joins Rithem Life Sciences’ Strategic Advisory Board | Business Wire
GT Biopharma Announces Positive Preclinical Results For GTB-5550 B7H3 TriKE™
BEVERLY HILLS, Calif., Aug. 3, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceutical company focused on developing target-directed, tri-specific Natural Killer (NK) cell engager therapies (TriKE™) incorporating interleukin 15 (IL-15) for the treatment of cancer, announced preclinical results for GTB-5550, its B7H3 TriKE™ product candidate as a prospective therapy for the treatment of several different types of cancers.
The ARIA Network Announces Exclusive Deal to Provide AR Powered Consumer Experiences Across Brookfield Properties Malls
Brookfield Properties to use augmented reality as immersive experiences in all Brookfield Properties, reaching consumers in over 100 malls nationwide
ARIA Exchange Announces Exclusive Fan Engagement NFT Partnership with the Major League Baseball Players Alumni Association
As part of its partnership with MLBPAA, ARIA Exchange will offer rare and unique NFTs to honor the significant contribution of baseball legends
Exclusive: Meet The ARIA Network, A New Media Company Seeking To Disrupt Advertising Via AR, NFTs And New Shoppable Experiences
CD Health Infrastructure Launches with First Acquisition, Targets National Roll-Up of Outpatient Medical Assets
GT Biopharma to be Added to the Russell 2000® Index
BEVERLY HILLS, Calif., June 8, 2021 /PRNewswire/ — GT Biopharma, Inc. (“GT Biopharma” or the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager (TriKE™) protein biologic technology platform, today announced that it is set to be added to the Russell 2000® Index at the conclusion of the Russell US Indexes annual reconstitution, effective at the opening of the U.S.
Spinogenix Granted FDA Orphan Drug Designation for SPG302 for the Treatment of Amyotrophic Lateral Sclerosis
Spinogenix Wins Grant to Advance Testing of Potential Oral ALS Therapy
Spinogenix Announces Grant by U.S. Department of Defense to Advance Novel Drug Candidate in Amyotrophic Lateral Sclerosis (ALS)
Gt biopharma announces fda data – gtb-3550 trike™ reduces cancer cells by 61.7% for a high-risk myelodysplastic syndromes (hr-mds) patient
GT Biopharma Announces TriKE™ For The Treatment Of Breast And GI Cancers
GT Biopharma Announces GTB-3550 TriKE(TM) Reduces Bone Marrow Blast Levels, Improves NK Cell Function and Proliferation, and No Toxicities Observed in AML and MDS Patients
Rithem Life Sciences Joins AHA’s Innovators’ Network
GT Biopharma Announces Selection of GTB-3550 Interim Results for Presentation at 62nd (ASH) American Society of Hematology Annual Meeting
GT Biopharma Announces Advisory Board Appointments
BolaWrap® Safely Restrains Suicidal Subject in Florida: Police Bodycam Footage Released
Lyniate and 4medica Announce Referral Partnership to Enhance Data Integrity and Interoperability
Urban Aeronautics signs deal with US-based Hatzolah Air to develop its flying ambulance
GT Biopharma Provides Update on Development of TriKE(TM) Therapeutic for Treatment of COVID-19 Infection
Cecelia Health Providing Critical Telehealth Support to Diabetes Specialty Clinics in Partnership with the Helmsley Charitable Trust
GT Biopharma Advances To Dose Level 3 with TriKE(TM) FDA Phase I/II Clinical Trial
Mellitus Health Names Steve Wubker Chief Executive Officer
GT Biopharma Announces Completion of $5.6 Million Bridge Financing
New AR Display From Ostendo Capable Of 150 Degree Field Of View At Low Cost
PureForm Global Signs Strategic Agreement to Distribute Products Containing PureForm CBD™ to More than 10,000 Retail Stores in the U.S.A.
Third European Country Purchases Wrap Technologies’ BolaWrap | Wrap Technologies, Inc.
GT Biopharma Announces Dosing Of New Patient In GTB-3550 TriKE(TM) Phase I/II Clinical Trial
Tuscaloosa County Sheriff’s Office Deploys Wrap Technologies’ BolaWrap | Wrap Technologies, Inc.
Importance of Patient Matching in Fighting COVID-19
GT Biopharma Announces Commencement of Retreatment of Patient Demonstrating Successful Clinical Benefit following GTB-3550 TriKE(TM) therapy
GT Biopharma up 20% on plan for coronavirus treatment
4medica and KPI Ninja Launch COVID-19 Alerts and Reporting Solution™ to Identify At-Risk Patients to Support Treatment and Prevention Efforts
Leading Stanford Alumni Scientists and Physicians Launch StartX Med COVID-19 Task Force
Wrap Technologies Receives Significant New International Orders
ILiAD Biotechnologies BPZE1 Pertussis Vaccine Reaches Full Enrollment In 300-Subject Multicenter Phase 2b Clinical Trial
Egis Portfolio Company MCP Announces Acquisition of URL Integration, Expanding its Data-Integration Capabilities • Egis Capital Partners
Egis Portfolio Company MCP Acquires Black & Veatch’s Public Safety Consulting Business • Egis Capital Partners
4medica Names Jorge Nobregas to Newly Created Position of Senior Vice President of Sales
Boeing to Explore Developing Israeli Ducted Fan Rotor Technology
Boeing partners with Tactical Robotics to develop VTOL tech
Gwyneth Paltrow backs clean cold medicine ≫
Self-flying war vehicle could be in the US as soon as 2022 ≫
Amydis Awarded NIH Ph2A Grant for Cerebral Amyloid Angiopathy ≫
The silver lining to Franky Zapata’s cross-Channel flight cloud ≫
Ingenu’s second-coming: claims $2bn pipeline, contract wins, slates rivals ≫
Micro-LED Market 2019 SWOT Analysis by Advancement to 2024 ≫
Sandstone Diagnostics Raises Additional Series A Financing to Accelerate Zero Delay™ Plasma Technology Development ≫
Genexa Provides Parents Cleaner Medicine Solutions for Infants and Children ≫
Global and US EHR-EMR Market will reach nearly USD 42,427.27 Mn in revenues by 2027 ≫
Optos and Amydis Establish Clinical Alliance to Develop Early Diagnostic Test for Alzheimer’s Disease ≫
Michael J. Fox Foundation Grants $7.7M for New Parkinson’s Research ≫
Insulin Algorithms Changes Name To Mellitus Health ≫
Mellitus Health and Smart Meter Announce Strategic Partnership for Connected Insulin Titration ≫
Spinogenix Awarded NIH Grant to Develop Novel Neurorestorative Therapeutics for Alzheimer’s Disease ≫
Spinogenix’s Spine Craft ≫
Genexa Rapidly Cleaning Up OTC Meds for Families ≫
Clinical trial of oral ALS therapy SPG302 is enrolling in Australia
Spinogenix Receives Approval from the Australia Human Research Ethics Committee to Initiate a Phase 1 Human Clinical Trial of SPG302, a Novel Regenerative Drug for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Novel regenerative drug, SPG302 promotes functional recovery of diaphragm muscle activity after cervical spinal cord injury
Amydis Awarded Third Grant From The Michael J. Fox Foundation To Support First-In-Human Study of a Retinal Tracer for Parkinson’s Disease
Trial to Detect Alpha-Synuclein Deposits in Patients’ Eyes Underway | AMDX-2011P Tracer Aims to Aid Monitoring, Diagnosing Parkinson’s | Parkinson’s News Today
Amydis Announces Enrollment of First Participants in PROBE, a Phase 1/2a Trial Evaluating a Novel Retinal Tracer in People with Amyotrophic Lateral Sclerosis or Parkinson’s Disease
GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650 — GlobeNewswire
Amydis Receives NIH Grant Award to Develop a Novel TDP-43 Retinal Tracer in Patients with ALS and FTD
ILiAD Biotechnologies Receives NIH Grant to Develop Novel Tuberculosis Vaccine using proprietary B-Tech Vector Platform | Business Wire
Amydis Appoints Dr. Robert N. Weinreb as First Chair of Scientific Advisory Board
PR NEWSWIRE: GT Biopharma Presents TriKE® Nanobody Pipeline (GTB-5550) Preclinical Multiple Myeloma Proof-of-Concept Data at 2022 EBMT Annual Meeting
GT Biopharma Presented Preclinical Data Demonstrating Novel Mesothelin-Targeted TriKE® Driving Cytotoxicity Across All Stages of Non-Small Cell Lung Cancer at ESMO TAT 2022
4medica Renews Focus on Improving Healthcare Data Quality in 2022 – 4medica
CD Healthcare Infrastructure Partners Facilitates Consumer-Centric Healthcare Delivery on the Philadelphia Main Line
GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021 :: GT Biopharma, Inc. (GTBP)
ILiAD Biotechnologies Announces First School-Age Participants Enrolled in BPZE1 Pertussis Vaccine Phase 2b SUPER Clinical Trial | Business Wire
FDA Grants ILiAD Biotechnologies Fast Track Designation for Next Generation Pertussis Vaccine BPZE1
CD Health Infrastructure Partners Facilitates Consumer‐Centric Healthcare Delivery on the Main Line
Amydis Announces Successful Completion of a Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer Targeting TDP43 for the Diagnosis of ALS
Amydis Announces Successful Completion of a Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer Targeting TDP43 for the Diagnosis of ALS
ResQR© Comprehensive Quality CPR AID Improves Performance of CPR Compressions in Untrained Laypersons – JEMS
Medicine Startup Genexa Raises $60 Million From VC-Led Group Including Gwyneth Paltrow, Don Cheadle
GT Biopharma Announces Issuance of Two New Patents Covering TriKE® Platform Technologies
BEVERLY HILLS, Calif., Sept. 9, 2021 /PRNewswire/ — GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, today announced that the United States Patent and Trademark Office (USPTO) has issued 2 new patents: Patent No. 11,098,100 – Broad coverage for TriKE proteins targeting any antigen Patent No.
Marshfield Clinic Health System Partners with 4medica to Modernize and Build Laboratory Reference and Outreach Business – 4medica
LifeScan and Cecelia Health Sign Expanded Multi-Year Partnership to Offer Live Diabetes Telehealth Support in Combination with OneTouch® Solutions Integrated Holistic Health Tools and OneTouch® Blood Glucose Monitoring
Former Los Angeles County Sheriff Jim McDonnell Joins Rithem Life Sciences’ Strategic Advisory Board | Business Wire
GT Biopharma Announces Positive Preclinical Results For GTB-5550 B7H3 TriKE™
BEVERLY HILLS, Calif., Aug. 3, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceutical company focused on developing target-directed, tri-specific Natural Killer (NK) cell engager therapies (TriKE™) incorporating interleukin 15 (IL-15) for the treatment of cancer, announced preclinical results for GTB-5550, its B7H3 TriKE™ product candidate as a prospective therapy for the treatment of several different types of cancers.
The ARIA Network Announces Exclusive Deal to Provide AR Powered Consumer Experiences Across Brookfield Properties Malls
Brookfield Properties to use augmented reality as immersive experiences in all Brookfield Properties, reaching consumers in over 100 malls nationwide
ARIA Exchange Announces Exclusive Fan Engagement NFT Partnership with the Major League Baseball Players Alumni Association
As part of its partnership with MLBPAA, ARIA Exchange will offer rare and unique NFTs to honor the significant contribution of baseball legends
Exclusive: Meet The ARIA Network, A New Media Company Seeking To Disrupt Advertising Via AR, NFTs And New Shoppable Experiences
CD Health Infrastructure Launches with First Acquisition, Targets National Roll-Up of Outpatient Medical Assets
GT Biopharma to be Added to the Russell 2000® Index
BEVERLY HILLS, Calif., June 8, 2021 /PRNewswire/ — GT Biopharma, Inc. (“GT Biopharma” or the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager (TriKE™) protein biologic technology platform, today announced that it is set to be added to the Russell 2000® Index at the conclusion of the Russell US Indexes annual reconstitution, effective at the opening of the U.S.
Spinogenix Granted FDA Orphan Drug Designation for SPG302 for the Treatment of Amyotrophic Lateral Sclerosis
Spinogenix Wins Grant to Advance Testing of Potential Oral ALS Therapy
Spinogenix Announces Grant by U.S. Department of Defense to Advance Novel Drug Candidate in Amyotrophic Lateral Sclerosis (ALS)
Gt biopharma announces fda data – gtb-3550 trike™ reduces cancer cells by 61.7% for a high-risk myelodysplastic syndromes (hr-mds) patient
GT Biopharma Announces TriKE™ For The Treatment Of Breast And GI Cancers
GT Biopharma Announces GTB-3550 TriKE(TM) Reduces Bone Marrow Blast Levels, Improves NK Cell Function and Proliferation, and No Toxicities Observed in AML and MDS Patients
Rithem Life Sciences Joins AHA’s Innovators’ Network
GT Biopharma Announces Selection of GTB-3550 Interim Results for Presentation at 62nd (ASH) American Society of Hematology Annual Meeting
GT Biopharma Announces Advisory Board Appointments
BolaWrap® Safely Restrains Suicidal Subject in Florida: Police Bodycam Footage Released
Lyniate and 4medica Announce Referral Partnership to Enhance Data Integrity and Interoperability
Urban Aeronautics signs deal with US-based Hatzolah Air to develop its flying ambulance
GT Biopharma Provides Update on Development of TriKE(TM) Therapeutic for Treatment of COVID-19 Infection
Cecelia Health Providing Critical Telehealth Support to Diabetes Specialty Clinics in Partnership with the Helmsley Charitable Trust
GT Biopharma Advances To Dose Level 3 with TriKE(TM) FDA Phase I/II Clinical Trial
Mellitus Health Names Steve Wubker Chief Executive Officer
GT Biopharma Announces Completion of $5.6 Million Bridge Financing
New AR Display From Ostendo Capable Of 150 Degree Field Of View At Low Cost
PureForm Global Signs Strategic Agreement to Distribute Products Containing PureForm CBD™ to More than 10,000 Retail Stores in the U.S.A.
Third European Country Purchases Wrap Technologies’ BolaWrap | Wrap Technologies, Inc.
GT Biopharma Announces Dosing Of New Patient In GTB-3550 TriKE(TM) Phase I/II Clinical Trial
Tuscaloosa County Sheriff’s Office Deploys Wrap Technologies’ BolaWrap | Wrap Technologies, Inc.
Importance of Patient Matching in Fighting COVID-19
GT Biopharma Announces Commencement of Retreatment of Patient Demonstrating Successful Clinical Benefit following GTB-3550 TriKE(TM) therapy
GT Biopharma up 20% on plan for coronavirus treatment
4medica and KPI Ninja Launch COVID-19 Alerts and Reporting Solution™ to Identify At-Risk Patients to Support Treatment and Prevention Efforts
Leading Stanford Alumni Scientists and Physicians Launch StartX Med COVID-19 Task Force
Wrap Technologies Receives Significant New International Orders
ILiAD Biotechnologies BPZE1 Pertussis Vaccine Reaches Full Enrollment In 300-Subject Multicenter Phase 2b Clinical Trial
Egis Portfolio Company MCP Announces Acquisition of URL Integration, Expanding its Data-Integration Capabilities • Egis Capital Partners
Egis Portfolio Company MCP Acquires Black & Veatch’s Public Safety Consulting Business • Egis Capital Partners
4medica Names Jorge Nobregas to Newly Created Position of Senior Vice President of Sales
Boeing to Explore Developing Israeli Ducted Fan Rotor Technology
Boeing partners with Tactical Robotics to develop VTOL tech
Gwyneth Paltrow backs clean cold medicine ≫
Self-flying war vehicle could be in the US as soon as 2022 ≫
Amydis Awarded NIH Ph2A Grant for Cerebral Amyloid Angiopathy ≫
The silver lining to Franky Zapata’s cross-Channel flight cloud ≫
Ingenu’s second-coming: claims $2bn pipeline, contract wins, slates rivals ≫
Micro-LED Market 2019 SWOT Analysis by Advancement to 2024 ≫
Sandstone Diagnostics Raises Additional Series A Financing to Accelerate Zero Delay™ Plasma Technology Development ≫
Genexa Provides Parents Cleaner Medicine Solutions for Infants and Children ≫
Global and US EHR-EMR Market will reach nearly USD 42,427.27 Mn in revenues by 2027 ≫
Optos and Amydis Establish Clinical Alliance to Develop Early Diagnostic Test for Alzheimer’s Disease ≫
Michael J. Fox Foundation Grants $7.7M for New Parkinson’s Research ≫
Insulin Algorithms Changes Name To Mellitus Health ≫
Mellitus Health and Smart Meter Announce Strategic Partnership for Connected Insulin Titration ≫
Spinogenix Awarded NIH Grant to Develop Novel Neurorestorative Therapeutics for Alzheimer’s Disease ≫
Spinogenix’s Spine Craft ≫
Genexa Rapidly Cleaning Up OTC Meds for Families ≫
Clinical trial of oral ALS therapy SPG302 is enrolling in Australia
Spinogenix Receives Approval from the Australia Human Research Ethics Committee to Initiate a Phase 1 Human Clinical Trial of SPG302, a Novel Regenerative Drug for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Novel regenerative drug, SPG302 promotes functional recovery of diaphragm muscle activity after cervical spinal cord injury
Amydis Awarded Third Grant From The Michael J. Fox Foundation To Support First-In-Human Study of a Retinal Tracer for Parkinson’s Disease
Trial to Detect Alpha-Synuclein Deposits in Patients’ Eyes Underway | AMDX-2011P Tracer Aims to Aid Monitoring, Diagnosing Parkinson’s | Parkinson’s News Today
Amydis Announces Enrollment of First Participants in PROBE, a Phase 1/2a Trial Evaluating a Novel Retinal Tracer in People with Amyotrophic Lateral Sclerosis or Parkinson’s Disease
GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650 — GlobeNewswire
Amydis Receives NIH Grant Award to Develop a Novel TDP-43 Retinal Tracer in Patients with ALS and FTD
ILiAD Biotechnologies Receives NIH Grant to Develop Novel Tuberculosis Vaccine using proprietary B-Tech Vector Platform | Business Wire
Amydis Appoints Dr. Robert N. Weinreb as First Chair of Scientific Advisory Board
PR NEWSWIRE: GT Biopharma Presents TriKE® Nanobody Pipeline (GTB-5550) Preclinical Multiple Myeloma Proof-of-Concept Data at 2022 EBMT Annual Meeting
GT Biopharma Presented Preclinical Data Demonstrating Novel Mesothelin-Targeted TriKE® Driving Cytotoxicity Across All Stages of Non-Small Cell Lung Cancer at ESMO TAT 2022
4medica Renews Focus on Improving Healthcare Data Quality in 2022 – 4medica
CD Healthcare Infrastructure Partners Facilitates Consumer-Centric Healthcare Delivery on the Philadelphia Main Line
GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021 :: GT Biopharma, Inc. (GTBP)
ILiAD Biotechnologies Announces First School-Age Participants Enrolled in BPZE1 Pertussis Vaccine Phase 2b SUPER Clinical Trial | Business Wire
FDA Grants ILiAD Biotechnologies Fast Track Designation for Next Generation Pertussis Vaccine BPZE1
CD Health Infrastructure Partners Facilitates Consumer‐Centric Healthcare Delivery on the Main Line
Amydis Announces Successful Completion of a Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer Targeting TDP43 for the Diagnosis of ALS
Amydis Announces Successful Completion of a Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer Targeting TDP43 for the Diagnosis of ALS
ResQR© Comprehensive Quality CPR AID Improves Performance of CPR Compressions in Untrained Laypersons – JEMS
Medicine Startup Genexa Raises $60 Million From VC-Led Group Including Gwyneth Paltrow, Don Cheadle
GT Biopharma Announces Issuance of Two New Patents Covering TriKE® Platform Technologies
BEVERLY HILLS, Calif., Sept. 9, 2021 /PRNewswire/ — GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, today announced that the United States Patent and Trademark Office (USPTO) has issued 2 new patents: Patent No. 11,098,100 – Broad coverage for TriKE proteins targeting any antigen Patent No.
Marshfield Clinic Health System Partners with 4medica to Modernize and Build Laboratory Reference and Outreach Business – 4medica
LifeScan and Cecelia Health Sign Expanded Multi-Year Partnership to Offer Live Diabetes Telehealth Support in Combination with OneTouch® Solutions Integrated Holistic Health Tools and OneTouch® Blood Glucose Monitoring
Former Los Angeles County Sheriff Jim McDonnell Joins Rithem Life Sciences’ Strategic Advisory Board | Business Wire
GT Biopharma Announces Positive Preclinical Results For GTB-5550 B7H3 TriKE™
BEVERLY HILLS, Calif., Aug. 3, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceutical company focused on developing target-directed, tri-specific Natural Killer (NK) cell engager therapies (TriKE™) incorporating interleukin 15 (IL-15) for the treatment of cancer, announced preclinical results for GTB-5550, its B7H3 TriKE™ product candidate as a prospective therapy for the treatment of several different types of cancers.
The ARIA Network Announces Exclusive Deal to Provide AR Powered Consumer Experiences Across Brookfield Properties Malls
Brookfield Properties to use augmented reality as immersive experiences in all Brookfield Properties, reaching consumers in over 100 malls nationwide
ARIA Exchange Announces Exclusive Fan Engagement NFT Partnership with the Major League Baseball Players Alumni Association
As part of its partnership with MLBPAA, ARIA Exchange will offer rare and unique NFTs to honor the significant contribution of baseball legends
Exclusive: Meet The ARIA Network, A New Media Company Seeking To Disrupt Advertising Via AR, NFTs And New Shoppable Experiences
CD Health Infrastructure Launches with First Acquisition, Targets National Roll-Up of Outpatient Medical Assets
GT Biopharma to be Added to the Russell 2000® Index
BEVERLY HILLS, Calif., June 8, 2021 /PRNewswire/ — GT Biopharma, Inc. (“GT Biopharma” or the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager (TriKE™) protein biologic technology platform, today announced that it is set to be added to the Russell 2000® Index at the conclusion of the Russell US Indexes annual reconstitution, effective at the opening of the U.S.
Spinogenix Granted FDA Orphan Drug Designation for SPG302 for the Treatment of Amyotrophic Lateral Sclerosis
Spinogenix Wins Grant to Advance Testing of Potential Oral ALS Therapy
Spinogenix Announces Grant by U.S. Department of Defense to Advance Novel Drug Candidate in Amyotrophic Lateral Sclerosis (ALS)
Gt biopharma announces fda data – gtb-3550 trike™ reduces cancer cells by 61.7% for a high-risk myelodysplastic syndromes (hr-mds) patient
GT Biopharma Announces TriKE™ For The Treatment Of Breast And GI Cancers
GT Biopharma Announces GTB-3550 TriKE(TM) Reduces Bone Marrow Blast Levels, Improves NK Cell Function and Proliferation, and No Toxicities Observed in AML and MDS Patients
Rithem Life Sciences Joins AHA’s Innovators’ Network
GT Biopharma Announces Selection of GTB-3550 Interim Results for Presentation at 62nd (ASH) American Society of Hematology Annual Meeting
GT Biopharma Announces Advisory Board Appointments
BolaWrap® Safely Restrains Suicidal Subject in Florida: Police Bodycam Footage Released
Lyniate and 4medica Announce Referral Partnership to Enhance Data Integrity and Interoperability
Urban Aeronautics signs deal with US-based Hatzolah Air to develop its flying ambulance
GT Biopharma Provides Update on Development of TriKE(TM) Therapeutic for Treatment of COVID-19 Infection
Cecelia Health Providing Critical Telehealth Support to Diabetes Specialty Clinics in Partnership with the Helmsley Charitable Trust
GT Biopharma Advances To Dose Level 3 with TriKE(TM) FDA Phase I/II Clinical Trial
Mellitus Health Names Steve Wubker Chief Executive Officer
GT Biopharma Announces Completion of $5.6 Million Bridge Financing
New AR Display From Ostendo Capable Of 150 Degree Field Of View At Low Cost
PureForm Global Signs Strategic Agreement to Distribute Products Containing PureForm CBD™ to More than 10,000 Retail Stores in the U.S.A.
Third European Country Purchases Wrap Technologies’ BolaWrap | Wrap Technologies, Inc.
GT Biopharma Announces Dosing Of New Patient In GTB-3550 TriKE(TM) Phase I/II Clinical Trial
Tuscaloosa County Sheriff’s Office Deploys Wrap Technologies’ BolaWrap | Wrap Technologies, Inc.
Importance of Patient Matching in Fighting COVID-19
GT Biopharma Announces Commencement of Retreatment of Patient Demonstrating Successful Clinical Benefit following GTB-3550 TriKE(TM) therapy
GT Biopharma up 20% on plan for coronavirus treatment
4medica and KPI Ninja Launch COVID-19 Alerts and Reporting Solution™ to Identify At-Risk Patients to Support Treatment and Prevention Efforts
Leading Stanford Alumni Scientists and Physicians Launch StartX Med COVID-19 Task Force
Wrap Technologies Receives Significant New International Orders
ILiAD Biotechnologies BPZE1 Pertussis Vaccine Reaches Full Enrollment In 300-Subject Multicenter Phase 2b Clinical Trial
Egis Portfolio Company MCP Announces Acquisition of URL Integration, Expanding its Data-Integration Capabilities • Egis Capital Partners
Egis Portfolio Company MCP Acquires Black & Veatch’s Public Safety Consulting Business • Egis Capital Partners
4medica Names Jorge Nobregas to Newly Created Position of Senior Vice President of Sales
Boeing to Explore Developing Israeli Ducted Fan Rotor Technology
Boeing partners with Tactical Robotics to develop VTOL tech
Gwyneth Paltrow backs clean cold medicine ≫
Self-flying war vehicle could be in the US as soon as 2022 ≫
Amydis Awarded NIH Ph2A Grant for Cerebral Amyloid Angiopathy ≫
The silver lining to Franky Zapata’s cross-Channel flight cloud ≫
Ingenu’s second-coming: claims $2bn pipeline, contract wins, slates rivals ≫
Micro-LED Market 2019 SWOT Analysis by Advancement to 2024 ≫
Sandstone Diagnostics Raises Additional Series A Financing to Accelerate Zero Delay™ Plasma Technology Development ≫
Genexa Provides Parents Cleaner Medicine Solutions for Infants and Children ≫
Global and US EHR-EMR Market will reach nearly USD 42,427.27 Mn in revenues by 2027 ≫
Optos and Amydis Establish Clinical Alliance to Develop Early Diagnostic Test for Alzheimer’s Disease ≫
Michael J. Fox Foundation Grants $7.7M for New Parkinson’s Research ≫
Insulin Algorithms Changes Name To Mellitus Health ≫
Mellitus Health and Smart Meter Announce Strategic Partnership for Connected Insulin Titration ≫
Spinogenix Awarded NIH Grant to Develop Novel Neurorestorative Therapeutics for Alzheimer’s Disease ≫
Spinogenix’s Spine Craft ≫
Genexa Rapidly Cleaning Up OTC Meds for Families ≫
Clinical trial of oral ALS therapy SPG302 is enrolling in Australia
Spinogenix Receives Approval from the Australia Human Research Ethics Committee to Initiate a Phase 1 Human Clinical Trial of SPG302, a Novel Regenerative Drug for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Novel regenerative drug, SPG302 promotes functional recovery of diaphragm muscle activity after cervical spinal cord injury
Amydis Awarded Third Grant From The Michael J. Fox Foundation To Support First-In-Human Study of a Retinal Tracer for Parkinson’s Disease
Trial to Detect Alpha-Synuclein Deposits in Patients’ Eyes Underway | AMDX-2011P Tracer Aims to Aid Monitoring, Diagnosing Parkinson’s | Parkinson’s News Today
Amydis Announces Enrollment of First Participants in PROBE, a Phase 1/2a Trial Evaluating a Novel Retinal Tracer in People with Amyotrophic Lateral Sclerosis or Parkinson’s Disease
GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650 — GlobeNewswire
Amydis Receives NIH Grant Award to Develop a Novel TDP-43 Retinal Tracer in Patients with ALS and FTD
ILiAD Biotechnologies Receives NIH Grant to Develop Novel Tuberculosis Vaccine using proprietary B-Tech Vector Platform | Business Wire
Amydis Appoints Dr. Robert N. Weinreb as First Chair of Scientific Advisory Board
PR NEWSWIRE: GT Biopharma Presents TriKE® Nanobody Pipeline (GTB-5550) Preclinical Multiple Myeloma Proof-of-Concept Data at 2022 EBMT Annual Meeting
GT Biopharma Presented Preclinical Data Demonstrating Novel Mesothelin-Targeted TriKE® Driving Cytotoxicity Across All Stages of Non-Small Cell Lung Cancer at ESMO TAT 2022
4medica Renews Focus on Improving Healthcare Data Quality in 2022 – 4medica
CD Healthcare Infrastructure Partners Facilitates Consumer-Centric Healthcare Delivery on the Philadelphia Main Line
GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021 :: GT Biopharma, Inc. (GTBP)
ILiAD Biotechnologies Announces First School-Age Participants Enrolled in BPZE1 Pertussis Vaccine Phase 2b SUPER Clinical Trial | Business Wire
FDA Grants ILiAD Biotechnologies Fast Track Designation for Next Generation Pertussis Vaccine BPZE1
CD Health Infrastructure Partners Facilitates Consumer‐Centric Healthcare Delivery on the Main Line
Amydis Announces Successful Completion of a Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer Targeting TDP43 for the Diagnosis of ALS
Amydis Announces Successful Completion of a Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer Targeting TDP43 for the Diagnosis of ALS
ResQR© Comprehensive Quality CPR AID Improves Performance of CPR Compressions in Untrained Laypersons – JEMS
Medicine Startup Genexa Raises $60 Million From VC-Led Group Including Gwyneth Paltrow, Don Cheadle
GT Biopharma Announces Issuance of Two New Patents Covering TriKE® Platform Technologies
BEVERLY HILLS, Calif., Sept. 9, 2021 /PRNewswire/ — GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, today announced that the United States Patent and Trademark Office (USPTO) has issued 2 new patents: Patent No. 11,098,100 – Broad coverage for TriKE proteins targeting any antigen Patent No.
Marshfield Clinic Health System Partners with 4medica to Modernize and Build Laboratory Reference and Outreach Business – 4medica
LifeScan and Cecelia Health Sign Expanded Multi-Year Partnership to Offer Live Diabetes Telehealth Support in Combination with OneTouch® Solutions Integrated Holistic Health Tools and OneTouch® Blood Glucose Monitoring
Former Los Angeles County Sheriff Jim McDonnell Joins Rithem Life Sciences’ Strategic Advisory Board | Business Wire
GT Biopharma Announces Positive Preclinical Results For GTB-5550 B7H3 TriKE™
BEVERLY HILLS, Calif., Aug. 3, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceutical company focused on developing target-directed, tri-specific Natural Killer (NK) cell engager therapies (TriKE™) incorporating interleukin 15 (IL-15) for the treatment of cancer, announced preclinical results for GTB-5550, its B7H3 TriKE™ product candidate as a prospective therapy for the treatment of several different types of cancers.
The ARIA Network Announces Exclusive Deal to Provide AR Powered Consumer Experiences Across Brookfield Properties Malls
Brookfield Properties to use augmented reality as immersive experiences in all Brookfield Properties, reaching consumers in over 100 malls nationwide
ARIA Exchange Announces Exclusive Fan Engagement NFT Partnership with the Major League Baseball Players Alumni Association
As part of its partnership with MLBPAA, ARIA Exchange will offer rare and unique NFTs to honor the significant contribution of baseball legends
Exclusive: Meet The ARIA Network, A New Media Company Seeking To Disrupt Advertising Via AR, NFTs And New Shoppable Experiences
CD Health Infrastructure Launches with First Acquisition, Targets National Roll-Up of Outpatient Medical Assets
GT Biopharma to be Added to the Russell 2000® Index
BEVERLY HILLS, Calif., June 8, 2021 /PRNewswire/ — GT Biopharma, Inc. (“GT Biopharma” or the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager (TriKE™) protein biologic technology platform, today announced that it is set to be added to the Russell 2000® Index at the conclusion of the Russell US Indexes annual reconstitution, effective at the opening of the U.S.
Spinogenix Granted FDA Orphan Drug Designation for SPG302 for the Treatment of Amyotrophic Lateral Sclerosis
Spinogenix Wins Grant to Advance Testing of Potential Oral ALS Therapy
Spinogenix Announces Grant by U.S. Department of Defense to Advance Novel Drug Candidate in Amyotrophic Lateral Sclerosis (ALS)
Gt biopharma announces fda data – gtb-3550 trike™ reduces cancer cells by 61.7% for a high-risk myelodysplastic syndromes (hr-mds) patient
GT Biopharma Announces TriKE™ For The Treatment Of Breast And GI Cancers
GT Biopharma Announces GTB-3550 TriKE(TM) Reduces Bone Marrow Blast Levels, Improves NK Cell Function and Proliferation, and No Toxicities Observed in AML and MDS Patients
Rithem Life Sciences Joins AHA’s Innovators’ Network
GT Biopharma Announces Selection of GTB-3550 Interim Results for Presentation at 62nd (ASH) American Society of Hematology Annual Meeting
GT Biopharma Announces Advisory Board Appointments
BolaWrap® Safely Restrains Suicidal Subject in Florida: Police Bodycam Footage Released
Lyniate and 4medica Announce Referral Partnership to Enhance Data Integrity and Interoperability
Urban Aeronautics signs deal with US-based Hatzolah Air to develop its flying ambulance
GT Biopharma Provides Update on Development of TriKE(TM) Therapeutic for Treatment of COVID-19 Infection
Cecelia Health Providing Critical Telehealth Support to Diabetes Specialty Clinics in Partnership with the Helmsley Charitable Trust
GT Biopharma Advances To Dose Level 3 with TriKE(TM) FDA Phase I/II Clinical Trial
Mellitus Health Names Steve Wubker Chief Executive Officer
GT Biopharma Announces Completion of $5.6 Million Bridge Financing
New AR Display From Ostendo Capable Of 150 Degree Field Of View At Low Cost
PureForm Global Signs Strategic Agreement to Distribute Products Containing PureForm CBD™ to More than 10,000 Retail Stores in the U.S.A.
Third European Country Purchases Wrap Technologies’ BolaWrap | Wrap Technologies, Inc.
GT Biopharma Announces Dosing Of New Patient In GTB-3550 TriKE(TM) Phase I/II Clinical Trial
Tuscaloosa County Sheriff’s Office Deploys Wrap Technologies’ BolaWrap | Wrap Technologies, Inc.
Importance of Patient Matching in Fighting COVID-19
GT Biopharma Announces Commencement of Retreatment of Patient Demonstrating Successful Clinical Benefit following GTB-3550 TriKE(TM) therapy
GT Biopharma up 20% on plan for coronavirus treatment
4medica and KPI Ninja Launch COVID-19 Alerts and Reporting Solution™ to Identify At-Risk Patients to Support Treatment and Prevention Efforts
Leading Stanford Alumni Scientists and Physicians Launch StartX Med COVID-19 Task Force
Wrap Technologies Receives Significant New International Orders
ILiAD Biotechnologies BPZE1 Pertussis Vaccine Reaches Full Enrollment In 300-Subject Multicenter Phase 2b Clinical Trial
Egis Portfolio Company MCP Announces Acquisition of URL Integration, Expanding its Data-Integration Capabilities • Egis Capital Partners
Egis Portfolio Company MCP Acquires Black & Veatch’s Public Safety Consulting Business • Egis Capital Partners
4medica Names Jorge Nobregas to Newly Created Position of Senior Vice President of Sales
Boeing to Explore Developing Israeli Ducted Fan Rotor Technology
Boeing partners with Tactical Robotics to develop VTOL tech
Gwyneth Paltrow backs clean cold medicine ≫
Self-flying war vehicle could be in the US as soon as 2022 ≫
Amydis Awarded NIH Ph2A Grant for Cerebral Amyloid Angiopathy ≫
The silver lining to Franky Zapata’s cross-Channel flight cloud ≫
Ingenu’s second-coming: claims $2bn pipeline, contract wins, slates rivals ≫
Micro-LED Market 2019 SWOT Analysis by Advancement to 2024 ≫
Sandstone Diagnostics Raises Additional Series A Financing to Accelerate Zero Delay™ Plasma Technology Development ≫
Genexa Provides Parents Cleaner Medicine Solutions for Infants and Children ≫
Global and US EHR-EMR Market will reach nearly USD 42,427.27 Mn in revenues by 2027 ≫
Optos and Amydis Establish Clinical Alliance to Develop Early Diagnostic Test for Alzheimer’s Disease ≫
Michael J. Fox Foundation Grants $7.7M for New Parkinson’s Research ≫
Insulin Algorithms Changes Name To Mellitus Health ≫
Mellitus Health and Smart Meter Announce Strategic Partnership for Connected Insulin Titration ≫
Spinogenix Awarded NIH Grant to Develop Novel Neurorestorative Therapeutics for Alzheimer’s Disease ≫
Spinogenix’s Spine Craft ≫
Genexa Rapidly Cleaning Up OTC Meds for Families ≫
Clinical trial of oral ALS therapy SPG302 is enrolling in Australia
Spinogenix Receives Approval from the Australia Human Research Ethics Committee to Initiate a Phase 1 Human Clinical Trial of SPG302, a Novel Regenerative Drug for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Novel regenerative drug, SPG302 promotes functional recovery of diaphragm muscle activity after cervical spinal cord injury
Amydis Awarded Third Grant From The Michael J. Fox Foundation To Support First-In-Human Study of a Retinal Tracer for Parkinson’s Disease
Trial to Detect Alpha-Synuclein Deposits in Patients’ Eyes Underway | AMDX-2011P Tracer Aims to Aid Monitoring, Diagnosing Parkinson’s | Parkinson’s News Today
Amydis Announces Enrollment of First Participants in PROBE, a Phase 1/2a Trial Evaluating a Novel Retinal Tracer in People with Amyotrophic Lateral Sclerosis or Parkinson’s Disease
GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650 — GlobeNewswire
Amydis Receives NIH Grant Award to Develop a Novel TDP-43 Retinal Tracer in Patients with ALS and FTD
ILiAD Biotechnologies Receives NIH Grant to Develop Novel Tuberculosis Vaccine using proprietary B-Tech Vector Platform | Business Wire
Amydis Appoints Dr. Robert N. Weinreb as First Chair of Scientific Advisory Board
PR NEWSWIRE: GT Biopharma Presents TriKE® Nanobody Pipeline (GTB-5550) Preclinical Multiple Myeloma Proof-of-Concept Data at 2022 EBMT Annual Meeting
GT Biopharma Presented Preclinical Data Demonstrating Novel Mesothelin-Targeted TriKE® Driving Cytotoxicity Across All Stages of Non-Small Cell Lung Cancer at ESMO TAT 2022
4medica Renews Focus on Improving Healthcare Data Quality in 2022 – 4medica
CD Healthcare Infrastructure Partners Facilitates Consumer-Centric Healthcare Delivery on the Philadelphia Main Line
GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021 :: GT Biopharma, Inc. (GTBP)
ILiAD Biotechnologies Announces First School-Age Participants Enrolled in BPZE1 Pertussis Vaccine Phase 2b SUPER Clinical Trial | Business Wire
FDA Grants ILiAD Biotechnologies Fast Track Designation for Next Generation Pertussis Vaccine BPZE1
CD Health Infrastructure Partners Facilitates Consumer‐Centric Healthcare Delivery on the Main Line
Amydis Announces Successful Completion of a Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer Targeting TDP43 for the Diagnosis of ALS
Amydis Announces Successful Completion of a Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer Targeting TDP43 for the Diagnosis of ALS
ResQR© Comprehensive Quality CPR AID Improves Performance of CPR Compressions in Untrained Laypersons – JEMS
Medicine Startup Genexa Raises $60 Million From VC-Led Group Including Gwyneth Paltrow, Don Cheadle
GT Biopharma Announces Issuance of Two New Patents Covering TriKE® Platform Technologies
BEVERLY HILLS, Calif., Sept. 9, 2021 /PRNewswire/ — GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, today announced that the United States Patent and Trademark Office (USPTO) has issued 2 new patents: Patent No. 11,098,100 – Broad coverage for TriKE proteins targeting any antigen Patent No.
Marshfield Clinic Health System Partners with 4medica to Modernize and Build Laboratory Reference and Outreach Business – 4medica
LifeScan and Cecelia Health Sign Expanded Multi-Year Partnership to Offer Live Diabetes Telehealth Support in Combination with OneTouch® Solutions Integrated Holistic Health Tools and OneTouch® Blood Glucose Monitoring
Former Los Angeles County Sheriff Jim McDonnell Joins Rithem Life Sciences’ Strategic Advisory Board | Business Wire
GT Biopharma Announces Positive Preclinical Results For GTB-5550 B7H3 TriKE™
BEVERLY HILLS, Calif., Aug. 3, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceutical company focused on developing target-directed, tri-specific Natural Killer (NK) cell engager therapies (TriKE™) incorporating interleukin 15 (IL-15) for the treatment of cancer, announced preclinical results for GTB-5550, its B7H3 TriKE™ product candidate as a prospective therapy for the treatment of several different types of cancers.
The ARIA Network Announces Exclusive Deal to Provide AR Powered Consumer Experiences Across Brookfield Properties Malls
Brookfield Properties to use augmented reality as immersive experiences in all Brookfield Properties, reaching consumers in over 100 malls nationwide
ARIA Exchange Announces Exclusive Fan Engagement NFT Partnership with the Major League Baseball Players Alumni Association
As part of its partnership with MLBPAA, ARIA Exchange will offer rare and unique NFTs to honor the significant contribution of baseball legends
Exclusive: Meet The ARIA Network, A New Media Company Seeking To Disrupt Advertising Via AR, NFTs And New Shoppable Experiences
CD Health Infrastructure Launches with First Acquisition, Targets National Roll-Up of Outpatient Medical Assets
GT Biopharma to be Added to the Russell 2000® Index
BEVERLY HILLS, Calif., June 8, 2021 /PRNewswire/ — GT Biopharma, Inc. (“GT Biopharma” or the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager (TriKE™) protein biologic technology platform, today announced that it is set to be added to the Russell 2000® Index at the conclusion of the Russell US Indexes annual reconstitution, effective at the opening of the U.S.
Spinogenix Granted FDA Orphan Drug Designation for SPG302 for the Treatment of Amyotrophic Lateral Sclerosis
Spinogenix Wins Grant to Advance Testing of Potential Oral ALS Therapy
Spinogenix Announces Grant by U.S. Department of Defense to Advance Novel Drug Candidate in Amyotrophic Lateral Sclerosis (ALS)
Gt biopharma announces fda data – gtb-3550 trike™ reduces cancer cells by 61.7% for a high-risk myelodysplastic syndromes (hr-mds) patient
GT Biopharma Announces TriKE™ For The Treatment Of Breast And GI Cancers
GT Biopharma Announces GTB-3550 TriKE(TM) Reduces Bone Marrow Blast Levels, Improves NK Cell Function and Proliferation, and No Toxicities Observed in AML and MDS Patients
Rithem Life Sciences Joins AHA’s Innovators’ Network
GT Biopharma Announces Selection of GTB-3550 Interim Results for Presentation at 62nd (ASH) American Society of Hematology Annual Meeting
GT Biopharma Announces Advisory Board Appointments
BolaWrap® Safely Restrains Suicidal Subject in Florida: Police Bodycam Footage Released
Lyniate and 4medica Announce Referral Partnership to Enhance Data Integrity and Interoperability
Urban Aeronautics signs deal with US-based Hatzolah Air to develop its flying ambulance
GT Biopharma Provides Update on Development of TriKE(TM) Therapeutic for Treatment of COVID-19 Infection
Cecelia Health Providing Critical Telehealth Support to Diabetes Specialty Clinics in Partnership with the Helmsley Charitable Trust
GT Biopharma Advances To Dose Level 3 with TriKE(TM) FDA Phase I/II Clinical Trial
Mellitus Health Names Steve Wubker Chief Executive Officer
GT Biopharma Announces Completion of $5.6 Million Bridge Financing
New AR Display From Ostendo Capable Of 150 Degree Field Of View At Low Cost
PureForm Global Signs Strategic Agreement to Distribute Products Containing PureForm CBD™ to More than 10,000 Retail Stores in the U.S.A.
Third European Country Purchases Wrap Technologies’ BolaWrap | Wrap Technologies, Inc.
GT Biopharma Announces Dosing Of New Patient In GTB-3550 TriKE(TM) Phase I/II Clinical Trial
Tuscaloosa County Sheriff’s Office Deploys Wrap Technologies’ BolaWrap | Wrap Technologies, Inc.
Importance of Patient Matching in Fighting COVID-19
GT Biopharma Announces Commencement of Retreatment of Patient Demonstrating Successful Clinical Benefit following GTB-3550 TriKE(TM) therapy
GT Biopharma up 20% on plan for coronavirus treatment
4medica and KPI Ninja Launch COVID-19 Alerts and Reporting Solution™ to Identify At-Risk Patients to Support Treatment and Prevention Efforts
Leading Stanford Alumni Scientists and Physicians Launch StartX Med COVID-19 Task Force
Wrap Technologies Receives Significant New International Orders
ILiAD Biotechnologies BPZE1 Pertussis Vaccine Reaches Full Enrollment In 300-Subject Multicenter Phase 2b Clinical Trial
Egis Portfolio Company MCP Announces Acquisition of URL Integration, Expanding its Data-Integration Capabilities • Egis Capital Partners
Egis Portfolio Company MCP Acquires Black & Veatch’s Public Safety Consulting Business • Egis Capital Partners
4medica Names Jorge Nobregas to Newly Created Position of Senior Vice President of Sales
Boeing to Explore Developing Israeli Ducted Fan Rotor Technology
Boeing partners with Tactical Robotics to develop VTOL tech
Gwyneth Paltrow backs clean cold medicine ≫
Self-flying war vehicle could be in the US as soon as 2022 ≫
Amydis Awarded NIH Ph2A Grant for Cerebral Amyloid Angiopathy ≫
The silver lining to Franky Zapata’s cross-Channel flight cloud ≫
Ingenu’s second-coming: claims $2bn pipeline, contract wins, slates rivals ≫
Micro-LED Market 2019 SWOT Analysis by Advancement to 2024 ≫
Sandstone Diagnostics Raises Additional Series A Financing to Accelerate Zero Delay™ Plasma Technology Development ≫
Genexa Provides Parents Cleaner Medicine Solutions for Infants and Children ≫
Global and US EHR-EMR Market will reach nearly USD 42,427.27 Mn in revenues by 2027 ≫
Optos and Amydis Establish Clinical Alliance to Develop Early Diagnostic Test for Alzheimer’s Disease ≫
Michael J. Fox Foundation Grants $7.7M for New Parkinson’s Research ≫
Insulin Algorithms Changes Name To Mellitus Health ≫
Mellitus Health and Smart Meter Announce Strategic Partnership for Connected Insulin Titration ≫
Spinogenix Awarded NIH Grant to Develop Novel Neurorestorative Therapeutics for Alzheimer’s Disease ≫
Spinogenix’s Spine Craft ≫
Genexa Rapidly Cleaning Up OTC Meds for Families ≫
LifeScan and Cecelia Health Sign Expanded Multi-Year Partnership to Offer Live Diabetes Telehealth Support in Combination with OneTouch® Solutions Integrated Holistic Health Tools and OneTouch® Blood Glucose Monitoring
Former Los Angeles County Sheriff Jim McDonnell Joins Rithem Life Sciences’ Strategic Advisory Board | Business Wire
GT Biopharma Announces Positive Preclinical Results For GTB-5550 B7H3 TriKE™
BEVERLY HILLS, Calif., Aug. 3, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceutical company focused on developing target-directed, tri-specific Natural Killer (NK) cell engager therapies (TriKE™) incorporating interleukin 15 (IL-15) for the treatment of cancer, announced preclinical results for GTB-5550, its B7H3 TriKE™ product candidate as a prospective therapy for the treatment of several different types of cancers.
The ARIA Network Announces Exclusive Deal to Provide AR Powered Consumer Experiences Across Brookfield Properties Malls
Brookfield Properties to use augmented reality as immersive experiences in all Brookfield Properties, reaching consumers in over 100 malls nationwide
ARIA Exchange Announces Exclusive Fan Engagement NFT Partnership with the Major League Baseball Players Alumni Association
As part of its partnership with MLBPAA, ARIA Exchange will offer rare and unique NFTs to honor the significant contribution of baseball legends
Exclusive: Meet The ARIA Network, A New Media Company Seeking To Disrupt Advertising Via AR, NFTs And New Shoppable Experiences
CD Health Infrastructure Launches with First Acquisition, Targets National Roll-Up of Outpatient Medical Assets
GT Biopharma to be Added to the Russell 2000® Index
BEVERLY HILLS, Calif., June 8, 2021 /PRNewswire/ — GT Biopharma, Inc. (“GT Biopharma” or the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager (TriKE™) protein biologic technology platform, today announced that it is set to be added to the Russell 2000® Index at the conclusion of the Russell US Indexes annual reconstitution, effective at the opening of the U.S.
Spinogenix Granted FDA Orphan Drug Designation for SPG302 for the Treatment of Amyotrophic Lateral Sclerosis
Spinogenix Wins Grant to Advance Testing of Potential Oral ALS Therapy
Spinogenix Announces Grant by U.S. Department of Defense to Advance Novel Drug Candidate in Amyotrophic Lateral Sclerosis (ALS)
Gt biopharma announces fda data – gtb-3550 trike™ reduces cancer cells by 61.7% for a high-risk myelodysplastic syndromes (hr-mds) patient
GT Biopharma Announces TriKE™ For The Treatment Of Breast And GI Cancers
GT Biopharma Announces GTB-3550 TriKE(TM) Reduces Bone Marrow Blast Levels, Improves NK Cell Function and Proliferation, and No Toxicities Observed in AML and MDS Patients
Rithem Life Sciences Joins AHA’s Innovators’ Network
GT Biopharma Announces Selection of GTB-3550 Interim Results for Presentation at 62nd (ASH) American Society of Hematology Annual Meeting
GT Biopharma Announces Advisory Board Appointments
BolaWrap® Safely Restrains Suicidal Subject in Florida: Police Bodycam Footage Released
Lyniate and 4medica Announce Referral Partnership to Enhance Data Integrity and Interoperability
Urban Aeronautics signs deal with US-based Hatzolah Air to develop its flying ambulance
GT Biopharma Provides Update on Development of TriKE(TM) Therapeutic for Treatment of COVID-19 Infection
Cecelia Health Providing Critical Telehealth Support to Diabetes Specialty Clinics in Partnership with the Helmsley Charitable Trust
GT Biopharma Advances To Dose Level 3 with TriKE(TM) FDA Phase I/II Clinical Trial
Mellitus Health Names Steve Wubker Chief Executive Officer
GT Biopharma Announces Completion of $5.6 Million Bridge Financing
New AR Display From Ostendo Capable Of 150 Degree Field Of View At Low Cost
PureForm Global Signs Strategic Agreement to Distribute Products Containing PureForm CBD™ to More than 10,000 Retail Stores in the U.S.A.
Third European Country Purchases Wrap Technologies’ BolaWrap | Wrap Technologies, Inc.
GT Biopharma Announces Dosing Of New Patient In GTB-3550 TriKE(TM) Phase I/II Clinical Trial
Tuscaloosa County Sheriff’s Office Deploys Wrap Technologies’ BolaWrap | Wrap Technologies, Inc.
Importance of Patient Matching in Fighting COVID-19
GT Biopharma Announces Commencement of Retreatment of Patient Demonstrating Successful Clinical Benefit following GTB-3550 TriKE(TM) therapy
GT Biopharma up 20% on plan for coronavirus treatment
4medica and KPI Ninja Launch COVID-19 Alerts and Reporting Solution™ to Identify At-Risk Patients to Support Treatment and Prevention Efforts
Leading Stanford Alumni Scientists and Physicians Launch StartX Med COVID-19 Task Force
Wrap Technologies Receives Significant New International Orders
ILiAD Biotechnologies BPZE1 Pertussis Vaccine Reaches Full Enrollment In 300-Subject Multicenter Phase 2b Clinical Trial
Egis Portfolio Company MCP Announces Acquisition of URL Integration, Expanding its Data-Integration Capabilities • Egis Capital Partners
Egis Portfolio Company MCP Acquires Black & Veatch’s Public Safety Consulting Business • Egis Capital Partners
4medica Names Jorge Nobregas to Newly Created Position of Senior Vice President of Sales
Boeing to Explore Developing Israeli Ducted Fan Rotor Technology
Boeing partners with Tactical Robotics to develop VTOL tech
Gwyneth Paltrow backs clean cold medicine ≫
Self-flying war vehicle could be in the US as soon as 2022 ≫
Amydis Awarded NIH Ph2A Grant for Cerebral Amyloid Angiopathy ≫
The silver lining to Franky Zapata’s cross-Channel flight cloud ≫
Ingenu’s second-coming: claims $2bn pipeline, contract wins, slates rivals ≫
Micro-LED Market 2019 SWOT Analysis by Advancement to 2024 ≫
Sandstone Diagnostics Raises Additional Series A Financing to Accelerate Zero Delay™ Plasma Technology Development ≫
Genexa Provides Parents Cleaner Medicine Solutions for Infants and Children ≫
Global and US EHR-EMR Market will reach nearly USD 42,427.27 Mn in revenues by 2027 ≫
Optos and Amydis Establish Clinical Alliance to Develop Early Diagnostic Test for Alzheimer’s Disease ≫
Michael J. Fox Foundation Grants $7.7M for New Parkinson’s Research ≫
Insulin Algorithms Changes Name To Mellitus Health ≫
Mellitus Health and Smart Meter Announce Strategic Partnership for Connected Insulin Titration ≫
Spinogenix Awarded NIH Grant to Develop Novel Neurorestorative Therapeutics for Alzheimer’s Disease ≫
Spinogenix’s Spine Craft ≫
Genexa Rapidly Cleaning Up OTC Meds for Families ≫
GT Biopharma Announces Positive Preclinical Results For GTB-5550 B7H3 TriKE™
BEVERLY HILLS, Calif., Aug. 3, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceutical company focused on developing target-directed, tri-specific Natural Killer (NK) cell engager therapies (TriKE™) incorporating interleukin 15 (IL-15) for the treatment of cancer, announced preclinical results for GTB-5550, its B7H3 TriKE™ product candidate as a prospective therapy for the treatment of several different types of cancers.
The ARIA Network Announces Exclusive Deal to Provide AR Powered Consumer Experiences Across Brookfield Properties Malls
Brookfield Properties to use augmented reality as immersive experiences in all Brookfield Properties, reaching consumers in over 100 malls nationwide
ARIA Exchange Announces Exclusive Fan Engagement NFT Partnership with the Major League Baseball Players Alumni Association
As part of its partnership with MLBPAA, ARIA Exchange will offer rare and unique NFTs to honor the significant contribution of baseball legends
Exclusive: Meet The ARIA Network, A New Media Company Seeking To Disrupt Advertising Via AR, NFTs And New Shoppable Experiences
CD Health Infrastructure Launches with First Acquisition, Targets National Roll-Up of Outpatient Medical Assets
GT Biopharma to be Added to the Russell 2000® Index
BEVERLY HILLS, Calif., June 8, 2021 /PRNewswire/ — GT Biopharma, Inc. (“GT Biopharma” or the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager (TriKE™) protein biologic technology platform, today announced that it is set to be added to the Russell 2000® Index at the conclusion of the Russell US Indexes annual reconstitution, effective at the opening of the U.S.
Spinogenix Granted FDA Orphan Drug Designation for SPG302 for the Treatment of Amyotrophic Lateral Sclerosis
Spinogenix Wins Grant to Advance Testing of Potential Oral ALS Therapy
Spinogenix Announces Grant by U.S. Department of Defense to Advance Novel Drug Candidate in Amyotrophic Lateral Sclerosis (ALS)
Gt biopharma announces fda data – gtb-3550 trike™ reduces cancer cells by 61.7% for a high-risk myelodysplastic syndromes (hr-mds) patient
GT Biopharma Announces TriKE™ For The Treatment Of Breast And GI Cancers
GT Biopharma Announces GTB-3550 TriKE(TM) Reduces Bone Marrow Blast Levels, Improves NK Cell Function and Proliferation, and No Toxicities Observed in AML and MDS Patients
Rithem Life Sciences Joins AHA’s Innovators’ Network
GT Biopharma Announces Selection of GTB-3550 Interim Results for Presentation at 62nd (ASH) American Society of Hematology Annual Meeting
GT Biopharma Announces Advisory Board Appointments
BolaWrap® Safely Restrains Suicidal Subject in Florida: Police Bodycam Footage Released
Lyniate and 4medica Announce Referral Partnership to Enhance Data Integrity and Interoperability
Urban Aeronautics signs deal with US-based Hatzolah Air to develop its flying ambulance
GT Biopharma Provides Update on Development of TriKE(TM) Therapeutic for Treatment of COVID-19 Infection
Cecelia Health Providing Critical Telehealth Support to Diabetes Specialty Clinics in Partnership with the Helmsley Charitable Trust
GT Biopharma Advances To Dose Level 3 with TriKE(TM) FDA Phase I/II Clinical Trial
Mellitus Health Names Steve Wubker Chief Executive Officer
GT Biopharma Announces Completion of $5.6 Million Bridge Financing
New AR Display From Ostendo Capable Of 150 Degree Field Of View At Low Cost
PureForm Global Signs Strategic Agreement to Distribute Products Containing PureForm CBD™ to More than 10,000 Retail Stores in the U.S.A.
Third European Country Purchases Wrap Technologies’ BolaWrap | Wrap Technologies, Inc.
GT Biopharma Announces Dosing Of New Patient In GTB-3550 TriKE(TM) Phase I/II Clinical Trial
Tuscaloosa County Sheriff’s Office Deploys Wrap Technologies’ BolaWrap | Wrap Technologies, Inc.
Importance of Patient Matching in Fighting COVID-19
GT Biopharma Announces Commencement of Retreatment of Patient Demonstrating Successful Clinical Benefit following GTB-3550 TriKE(TM) therapy
GT Biopharma up 20% on plan for coronavirus treatment
4medica and KPI Ninja Launch COVID-19 Alerts and Reporting Solution™ to Identify At-Risk Patients to Support Treatment and Prevention Efforts
Leading Stanford Alumni Scientists and Physicians Launch StartX Med COVID-19 Task Force
Wrap Technologies Receives Significant New International Orders
ILiAD Biotechnologies BPZE1 Pertussis Vaccine Reaches Full Enrollment In 300-Subject Multicenter Phase 2b Clinical Trial
Egis Portfolio Company MCP Announces Acquisition of URL Integration, Expanding its Data-Integration Capabilities • Egis Capital Partners
Egis Portfolio Company MCP Acquires Black & Veatch’s Public Safety Consulting Business • Egis Capital Partners
4medica Names Jorge Nobregas to Newly Created Position of Senior Vice President of Sales
Boeing to Explore Developing Israeli Ducted Fan Rotor Technology
Boeing partners with Tactical Robotics to develop VTOL tech
Gwyneth Paltrow backs clean cold medicine ≫
Self-flying war vehicle could be in the US as soon as 2022 ≫
Amydis Awarded NIH Ph2A Grant for Cerebral Amyloid Angiopathy ≫
The silver lining to Franky Zapata’s cross-Channel flight cloud ≫
Ingenu’s second-coming: claims $2bn pipeline, contract wins, slates rivals ≫
Micro-LED Market 2019 SWOT Analysis by Advancement to 2024 ≫
Sandstone Diagnostics Raises Additional Series A Financing to Accelerate Zero Delay™ Plasma Technology Development ≫
Genexa Provides Parents Cleaner Medicine Solutions for Infants and Children ≫
Global and US EHR-EMR Market will reach nearly USD 42,427.27 Mn in revenues by 2027 ≫
Optos and Amydis Establish Clinical Alliance to Develop Early Diagnostic Test for Alzheimer’s Disease ≫
Michael J. Fox Foundation Grants $7.7M for New Parkinson’s Research ≫
Insulin Algorithms Changes Name To Mellitus Health ≫
Mellitus Health and Smart Meter Announce Strategic Partnership for Connected Insulin Titration ≫
Spinogenix Awarded NIH Grant to Develop Novel Neurorestorative Therapeutics for Alzheimer’s Disease ≫
Spinogenix’s Spine Craft ≫
Genexa Rapidly Cleaning Up OTC Meds for Families ≫
OUR NAME
The Merkava or “heavenly chariot” in mysticism is the name given to the first vision of the prophet Ezekiel. The word Merkava is derived from the root word that means ‘to ride.’ In his prophecy, Ezekiel sees the throne or chariot of God supported by the celestial beings and different classes of angels that move to and fro surrounded by bright copper emitting electric flashes of light. The chariot is described as a four-wheeled vehicle and is being driven by the heavenly creatures with the Lord on his throne above. Merkava also refers to the complex process of assembling components. The Merkava may be considered the first high-tech spiritual/material platform through which reality is derived.
At Merkava Holdings, we identify platform-level technologies that will drastically alter the way things are done in multiple disciplines. From companies like Ostendo Technologies that is building the first quantum photonic foundry and affords the ability to control light at the photonic level to SELFA Diagnostics that harnesses the power of the semiconductor to allow real-time, point of care testing of blood and other biological fluids; Urban Aeronautics that has developed a wingless, internal rotor, vertical takeoff, “go-anywhere land-anywhere” vehicle for military and civilian search and rescue missions; Amydis Diagnostics that has produced a small molecule used to detect the presence of amyloid that accumulates in a number of disease states such as Alzheimer’s, Parkinson’s, Creutzfeld-Jacob, Traumatic Brain Injury and Preeclampsia of pregnancy; Spinogenix has discovered a molecule that improves cognition in traumatic brain injury, Alzheimer’s Disease and normal animal models by increasing neuronal spine density in the brain. Merkava invests in powerful ideas and infrastructure to help manifest them into reality.
DR. PHILIP WERTHMAN
Dr. Werthman is a world-renowned microsurgeon, male fertility, and men’s health expert who brings a unique set of skills, relationships and perspective to the venture capital and investment world. Before going to medical school, he obtained his bachelor’s degree in Environmental Neuropsychology having conducted original research in exploring how the environment affects neurotransmitters and behavior. Dr. Wetrhman graduated as his medical school’s class Valedictorian and was recognized for obtaining the highest marks in the country of the National Medical Boards examination. From there he went through residency training in the Department’s of Surgery and Urology at UCLA. Dr. Werthman conducted award-winning scientific research and published early articles in gene therapy while working in UCLA’s Liver Transplant Laboratory. After residency, Dr. Werthman pursued a fellowship in Andrology and Microsurgery.